JP4989490B2 - 腸内細菌による生物活性物質の制御された産生および送達 - Google Patents

腸内細菌による生物活性物質の制御された産生および送達 Download PDF

Info

Publication number
JP4989490B2
JP4989490B2 JP2007551749A JP2007551749A JP4989490B2 JP 4989490 B2 JP4989490 B2 JP 4989490B2 JP 2007551749 A JP2007551749 A JP 2007551749A JP 2007551749 A JP2007551749 A JP 2007551749A JP 4989490 B2 JP4989490 B2 JP 4989490B2
Authority
JP
Japan
Prior art keywords
muil2
obatas
growth factor
bacterium
xylan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007551749A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008527988A (ja
JP2008527988A5 (enExample
Inventor
カーディング，サイモン
ファラー，マーク
Original Assignee
プラント・バイオサイエンス・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プラント・バイオサイエンス・リミテッド filed Critical プラント・バイオサイエンス・リミテッド
Publication of JP2008527988A publication Critical patent/JP2008527988A/ja
Publication of JP2008527988A5 publication Critical patent/JP2008527988A5/ja
Application granted granted Critical
Publication of JP4989490B2 publication Critical patent/JP4989490B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/18—Baker's yeast; Brewer's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007551749A 2005-01-25 2006-01-24 腸内細菌による生物活性物質の制御された産生および送達 Expired - Fee Related JP4989490B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0501540.9 2005-01-25
GBGB0501540.9A GB0501540D0 (en) 2005-01-25 2005-01-25 Controlled production and delivery of biologically active agents by gut bacteria
PCT/GB2006/000222 WO2006079790A2 (en) 2005-01-25 2006-01-24 Controlled production and delivery of biologically active agents by gut bacteria

Publications (3)

Publication Number Publication Date
JP2008527988A JP2008527988A (ja) 2008-07-31
JP2008527988A5 JP2008527988A5 (enExample) 2012-05-10
JP4989490B2 true JP4989490B2 (ja) 2012-08-01

Family

ID=34259652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007551749A Expired - Fee Related JP4989490B2 (ja) 2005-01-25 2006-01-24 腸内細菌による生物活性物質の制御された産生および送達

Country Status (10)

Country Link
US (1) US7988961B2 (enExample)
EP (1) EP1841875B1 (enExample)
JP (1) JP4989490B2 (enExample)
KR (1) KR101291960B1 (enExample)
AT (1) ATE483811T1 (enExample)
CA (1) CA2640343C (enExample)
DE (1) DE602006017331D1 (enExample)
ES (1) ES2353721T3 (enExample)
GB (1) GB0501540D0 (enExample)
WO (1) WO2006079790A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008317000B2 (en) * 2007-10-26 2014-10-23 Brenda E. Moore Probiotic compositions and methods for inducing and supporting weight loss
EP2258844A1 (en) 2009-05-28 2010-12-08 Helmholtz Zentrum Für Infektionsforschung Tumour-specific bacterial promoter elements
CN102462837B (zh) * 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
US10047405B2 (en) 2013-12-20 2018-08-14 President And Fellows Of Harvard College Engineered genetic enteric sensor bacteria and uses thereof
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
WO2016106343A1 (en) * 2014-12-22 2016-06-30 Massachusetts Institute Of Technology Probiotic organisms for diagnosis, monitoring, and treatment of inflammatory bowel disease
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
JP7095993B2 (ja) * 2015-03-02 2022-07-05 シンロジック オペレーティング カンパニー インコーポレイテッド 消化管炎症低下および／または消化管粘膜バリア強化の利益を享受する疾患処置のために操作された細菌
EP3294760B1 (en) 2015-05-13 2021-03-24 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
US11685925B2 (en) 2015-10-30 2023-06-27 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
AU2016356684C1 (en) 2015-11-16 2022-11-10 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
US11766461B2 (en) 2016-04-20 2023-09-26 The Board of Trustees of the Stanford Junior Compositions and methods for nucleic acid expression and protein secretion in Bacteroides
EP3554518A4 (en) 2016-12-15 2020-07-29 The Board of Trustees of the Leland Stanford Junior University COMPOSITIONS AND METHODS FOR MODULATING THE GROWTH OF A GENETICALLY MODIFIED INTESTINAL BACTERIAL CELL
WO2018152133A1 (en) * 2017-02-14 2018-08-23 California Institute Of Technology Modulation of microbial synthesis of 4-etylphenol and 4-ethylphenol sulfate in behavior and disease
WO2018152306A1 (en) * 2017-02-15 2018-08-23 President And Fellows Of Harvard College Modulation of host immune cell populations using gut microbiota
WO2018183685A1 (en) * 2017-03-29 2018-10-04 President And Fellows Of Harvard College Methods of regulating gene expression in a cell
BR112021011221A2 (pt) 2018-12-10 2021-08-31 Novome Biotechnologies, Inc. Métodos e composições para tratar hiperoxalúria
JP2023518184A (ja) 2020-03-20 2023-04-28 シンロジック オペレーティング カンパニー インコーポレイテッド 高フェニルアラニン血症を軽減するように遺伝子改変された微生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569604A1 (en) * 1992-04-07 1993-11-18 Societe Des Produits Nestle S.A. Integrative gene-expression in Streptococcus salivarius ssp.thermophilus
ATE356217T1 (de) * 1999-09-10 2007-03-15 Secr Defence Rekombinante mikroorganismen
JP2001275680A (ja) * 2000-03-31 2001-10-09 Yakult Honsha Co Ltd β−１，３−キシラナーゼ遺伝子、該遺伝子を導入した微生物、及びβ−１，３−キシラナーゼの製造法
JP2003144200A (ja) * 2001-11-07 2003-05-20 Yakult Honsha Co Ltd バクテロイデスグループ細菌用プローブおよびこれを用いた検出方法

Also Published As

Publication number Publication date
ES2353721T3 (es) 2011-03-04
GB0501540D0 (en) 2005-03-02
JP2008527988A (ja) 2008-07-31
ATE483811T1 (de) 2010-10-15
WO2006079790A2 (en) 2006-08-03
CA2640343A1 (en) 2006-08-03
DE602006017331D1 (de) 2010-11-18
EP1841875B1 (en) 2010-10-06
EP1841875A2 (en) 2007-10-10
WO2006079790A3 (en) 2006-12-21
KR101291960B1 (ko) 2013-08-09
CA2640343C (en) 2014-01-14
US20080131402A1 (en) 2008-06-05
KR20070108882A (ko) 2007-11-13
US7988961B2 (en) 2011-08-02

Similar Documents

Publication Publication Date Title
JP4989490B2 (ja) 腸内細菌による生物活性物質の制御された産生および送達
EP2344626B1 (en) Reduced colonization of microbes at the mucosa
US8759088B2 (en) Lactococcus promoters and uses thereof
JP5085547B2 (ja) 生理活性ポリペプチドの細菌性送達
US20120144509A1 (en) Novel strains of helicobacter pylori and uses thereof
US20110318379A1 (en) Vaccine for Porcine Post-Weaning Diarrhea Caused by Enterotoxigenic Escherichia Coli
CN118813511A (zh) 稳定表达il-10和胰岛素的遗传修饰的细菌
EP2597151A2 (en) Recombinant microorganisms, methods for preparing vaccine strains, antigens, and vector vaccine compositions of same, uses thereof, and related antibodies, diagnostic kit, and treatment and/or prophylactic methods
Ogita et al. Suppression of Th17 response by Streptococcus thermophilus ST28 through induction of IFN-γ
CN1760360A (zh) 发酵乳酸杆菌GM－090及其在刺激INF－γ分泌及/或治疗过敏的用途
Kim et al. Live attenuated Salmonella enterica serovar Typhimurium expressing swine interferon-α has antiviral activity and alleviates clinical signs induced by infection with transmissible gastroenteritis virus in piglets
CN107073106A (zh) 用于治疗泌尿生殖系统癌症的减毒或失活病原性大肠杆菌
US20250108076A1 (en) Methods for treatment of non-alcoholic fatty liver diseases (nafld) using advanced microbiome therapeutics
RU2812766C2 (ru) Хлорид-индуцируемая прокариотическая система экспрессии
Remaut et al. Clinical potential of Lactococcus lactis mediated delivery of human interleukin-10 and trefoil factors
CN100350038C (zh) 表达绿色荧光蛋白的乳酸杆菌基因工程体
CN120392992A (zh) 用于产肠毒素大肠杆菌f18菌毛型的乳酸乳球菌载体口服疫苗及应用
Sheil et al. Probiotics: A Role in Therapy for Inflammatory Bowel Disease
Steidler In Situ Delivery of Cytokines at Mucosal Surfaces by Genetically Engineered
HK1236565A1 (en) Reduced colonization of microbes at the mucosa

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090122

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20110119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111125

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111222

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120221

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120312

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120410

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120427

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150511

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees